Nuvectis Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCT research report →
Companywww.nuvectis.com
Nuvectis Pharma, Inc. , a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases.
- CEO
- Ron Bentsur
- IPO
- 2022
- Employees
- 13
- HQ
- Fort Lee, NJ, US
Price Chart
Valuation
- Market Cap
- $281.97M
- P/E
- -9.16
- P/S
- 0.00
- P/B
- 17.50
- EV/EBITDA
- -9.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -147.78%
- ROIC
- -198.78%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,442,000 · -39.17%
- EPS
- $-1.32 · -18.92%
- Op Income
- $-27,574,000
- FCF YoY
- -30.72%
Performance & Tape
- 52W High
- $13.34
- 52W Low
- $5.55
- 50D MA
- $8.95
- 200D MA
- $7.57
- Beta
- -0.12
- Avg Volume
- 71.20K
Get TickerSpark's AI analysis on NVCT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 6, 26 | Shemesh Shay | other | 150,000 |
| Jan 6, 26 | BENTSUR RON | other | 150,000 |
| Jan 6, 26 | Poradosu Enrique | other | 150,000 |
| Jan 6, 26 | Carson Michael J. | other | 61,200 |
| Nov 5, 25 | BENTSUR RON | buy | 5,000 |
| Nov 5, 25 | Sanchez Juan | buy | 13,000 |
| Nov 5, 25 | Kaplan Matthew L. | buy | 11,000 |
| Sep 22, 25 | Sanchez Juan | other | 30,000 |
| Sep 22, 25 | Sanchez Juan | other | 0 |
| Sep 22, 25 | Sanchez Juan | other | 0 |
Our NVCT Coverage
We haven't published any research on NVCT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVCT Report →